23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › SUPERNUS PHARMACEUTICALS INC. › 2023-2024

SUPERNUS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and SUPERNUS PHARMACEUTICALS INC.’s Form 8-K, filed June 17, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 304Asset managers, any item
  • 1,843Fund votes
  • June 14, 2024Meeting date

Results at a glance

Meeting of June 14, 2024: 5 items on SUPERNUS PHARMACEUTICALS INC.’s Form 8-K, filed June 17, 2024: 5 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13F, 3.0%, as of September 30, 2026)

Explore SUPERNUS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SUPERNUS PHARMACEUTICALS INC.

These tallies are SUPERNUS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 17, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SUPERNUS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 14, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Georges Gemayel, Ph.D 48,410,580---- 2,121,5051,945,574 96%Passed (calculated)—
Elect Director: Bethany L. Sensenig 48,568,282---- 1,963,8031,945,574 96%Passed (calculated)—
2. To approve, on a non-binding basis, the compensation paid to our named executive officers 48,217,5392,290,23724,309 --1,945,574 95%Passed (calculated)—
3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2024 52,182,042272,90622,711 --0 99.5%Passed (calculated)—
4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc 45,522,1664,972,67537,244 --1,945,574 90%Passed (calculated)—

Source: SUPERNUS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 17, 2024 — read the filing on EDGAR.

How asset managers voted at the SUPERNUS PHARMACEUTICALS INC. 2023-2024 meeting

304 asset managers disclosed a vote on at least one SUPERNUS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Georges Gemayel, Ph.D

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 48,410,580WITHHELD: 2,121,505
Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Georges Gemayel, Ph.D.

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Georges Gemayel, Ph.D”): 48,410,580 for, 2,121,505 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 26,214,022 for, 874,729 withheld, 1,822 unknown.

FOR
FOR: 26,214,022WITHHOLD: 874,729UNKNOWN: 1,822
Largest asset managers voting on “to elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,977,6570 00For
BlackRock5,666,0930 00For
Dimensional2,250,5590 00For
Delaware/Macquarie2,074,7470 00For
Fidelity1,251,6260 00For
State Street924,7980 0293For
Loomis Sayles800,9350 00For
PROFESSIONALLY MANAGED PORTFOLIOS570,0000 00For
Charles Schwab567,3920 00For
Columbia Threadneedle515,8370 00For
Invesco00 0430,653Withhold
Victory Capital334,7980 00For
AMG FUNDS328,1740 00For
MoA Funds Corp273,6300 00For
Brighthouse238,6220 033,692Mixed
Bridge Builder Trust264,2700 00For
T. Rowe Price00 0234,311Withhold
TIAA226,9320 00For
Tributary Funds, Inc.225,0050 00For
John Hancock189,3910 00For
Lincoln Financial176,2180 00For
THIRD AVENUE TRUST159,7170 00For
Empower112,8380 039,636Mixed
Jackson National131,1140 00For
Equitable75,6240 050,200Mixed

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Elect Director: Bethany L. Sensenig

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 48,568,282WITHHELD: 1,963,803
Details: description as filed, official tally, votes by 98 asset managers

Description as filed by funds: to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: Bethany L. Sensenig

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bethany L. Sensenig”): 48,568,282 for, 1,963,803 withheld, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 98 asset managers below reported 26,469,869 for, 609,162 withheld, 1,822 unknown.

FOR
FOR: 26,469,869WITHHOLD: 609,162UNKNOWN: 1,822
Largest asset managers voting on “to elect two (2) directors to hold office for the ensuing three years and until their successors have been dul” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,977,6570 00For
BlackRock5,666,0930 00For
Dimensional2,250,5590 00For
Delaware/Macquarie2,074,7470 00For
Fidelity1,251,6260 00For
State Street925,0910 00For
Loomis Sayles800,9350 00For
PROFESSIONALLY MANAGED PORTFOLIOS570,0000 00For
Charles Schwab567,3920 00For
Columbia Threadneedle515,8370 00For
Invesco430,6530 00For
Victory Capital334,7980 00For
AMG FUNDS00 0328,174Withhold
MoA Funds Corp273,6300 00For
Brighthouse272,3140 00For
Bridge Builder Trust264,2700 00For
T. Rowe Price234,3110 00For
TIAA226,9320 00For
Tributary Funds, Inc.225,0050 00For
John Hancock62,5020 0126,889Mixed
Lincoln Financial176,2180 00For
THIRD AVENUE TRUST159,7170 00For
Empower152,4740 00For
Jackson National131,1140 00For
Equitable125,8240 00For

Showing the 25 largest of 98 asset managers. All 98 are in the interactive database (link above).

To act upon a proposal to amend the Supernus Pharmaceuticals, Inc

Calculated outcomeCOMPENSATIONPassed (calculated)

Combines 5 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 45,522,166AGAINST: 4,972,675
Details: description as filed, official tally, votes by 100 asset managers

Description as filed by funds: to consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the plan and make certain technical updates; and

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“4. To act upon a proposal to amend the Supernus Pharmaceuticals, Inc”): 45,522,166 for, 4,972,675 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 100 asset managers below reported 25,157,250 for, 1,874,752 against, 17,193 abstained, 1,822 unknown.

FOR
FOR: 25,157,250AGAINST: 1,874,752ABSTAIN: 17,193UNKNOWN: 1,822
Largest asset managers voting on “to consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to ” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,977,6570 00For
BlackRock5,666,0930 00For
Dimensional2,250,5590 00For
Delaware/Macquarie2,074,7470 00For
Fidelity1,251,6260 00For
State Street1,891923,200 00Against
Loomis Sayles800,9350 00For
PROFESSIONALLY MANAGED PORTFOLIOS570,0000 00For
Charles Schwab567,3920 00For
Columbia Threadneedle515,8370 00For
Invesco430,6530 00For
Victory Capital334,7980 00For
AMG FUNDS0328,174 00Against
MoA Funds Corp273,6300 00For
Brighthouse272,3140 00For
Bridge Builder Trust262,7341,536 00For
T. Rowe Price234,3110 00For
TIAA226,9320 00For
Tributary Funds, Inc.0225,005 00Against
John Hancock62,502126,889 00Mixed
Lincoln Financial135,02841,190 00Mixed
THIRD AVENUE TRUST0159,717 00Against
Jackson National131,1140 00For
Equitable125,8240 00For
CARILLON SERIES TRUST121,2350 00For

Showing the 25 largest of 100 asset managers. All 100 are in the interactive database (link above).

To approve, on a non-binding basis, the compensation paid to our named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 12 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 48,217,539AGAINST: 2,290,237

Prior year: 97.0% for (June 16, 2023 meeting) ▼ 1.5 pts

Details: description as filed, official tally, votes by 303 asset managers

Description as filed by funds: to approve, on a non-binding basis, the compensation paid to our named executive officers;

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“2. To approve, on a non-binding basis, the compensation paid to our named executive officers”): 48,217,539 for, 2,290,237 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of SUPERNUS PHARMACEUTICALS INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 98 asset managers voting on “to approve, on a non-binding basis, the compensation paid to our named executive officers;” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,977,6570 00For
BlackRock5,666,0930 00For
Dimensional2,250,5590 00For
Delaware/Macquarie2,074,7470 00For
Fidelity1,251,6260 00For
State Street924,798293 00For
Loomis Sayles800,9350 00For
PROFESSIONALLY MANAGED PORTFOLIOS570,0000 00For
Charles Schwab567,3920 00For
Columbia Threadneedle515,8370 00For
Invesco430,6530 00For
Victory Capital334,7980 00For
AMG FUNDS328,1740 00For
MoA Funds Corp273,6300 00For
Brighthouse272,3140 00For
Bridge Builder Trust264,2700 00For
T. Rowe Price234,3110 00For
TIAA226,9320 00For
Tributary Funds, Inc.225,0050 00For
John Hancock189,3910 00For
Lincoln Financial176,2180 00For
THIRD AVENUE TRUST159,7170 00For
Jackson National131,1140 00For
Equitable125,8240 00For
CARILLON SERIES TRUST121,2350 00For

Fund voting reports, all 98 managers: 26,756,528 for, 275,344 against, 17,193 abstained, 1,822 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 228 asset managers voting on “to approve, on a non-binding basis, the compensation paid to our named executive officers;” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
ARMISTICE CAPITAL, LLC2,928,6210 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST2,447,4450 00For
BlackRock2,109,00011,690 00For
Polar Capital Holdings Plc1,940,5100 00For
State Street1,906,218293 00For
Stephens Investment Management Group LLC1,440,0570 00For
GEODE CAPITAL MANAGEMENT, LLC1,257,0240 00For
GW&K Investment Management, LLC1,095,2948,323 00For
Aristotle Capital Boston, LLC978,6290 00For
CONGRESS ASSET MANAGEMENT CO /MA882,9560 00For
Renaissance814,7870 00For
ASHFORD CAPITAL MANAGEMENT INC737,1650 00For
Charles Schwab624,5130 00For
Victory Capital618,0850 00For
Northern Trust537,08243 00For
PICTET ASSET MANAGEMENT SA483,4680 00For
Invesco451,5860 00For
MELLON INVESTMENTS Corp404,9080 00For
RICE HALL JAMES & ASSOCIATES, LLC5,821379,363 00Against
T. Rowe Price359,3720 00For
SCHRODER INVESTMENT MANAGEMENT GROUP0357,681 00Against
Woodline Partners LP323,4430 00For
Tributary Capital Management, LLC321,3450 00For
PRINCIPAL GLOBAL INVESTORS282,2990 00For
MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC280,9240 00For

Institutional-manager reports, all 228 managers: 27,132,053 for, 1,700,535 against, 12,633 not voted, 2,684 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 52,182,042AGAINST: 272,906

Prior year: 99.2% for (June 16, 2023 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024;

SUPERNUS PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of the appointment of KPMG LLP as the Company's independent public accounting firm for the fiscal year ending December 31, 2024”): 52,182,042 for, 272,906 against, per its Form 8-K filed June 17, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 27,071,482 for, 76 against, 17,193 abstained, 1,822 unknown.

FOR
FOR: 27,071,482AGAINST: 76ABSTAIN: 17,193UNKNOWN: 1,822
Largest asset managers voting on “to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year” at SUPERNUS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard6,977,6570 00For
BlackRock5,666,0930 00For
Dimensional2,250,5590 00For
Delaware/Macquarie2,074,7470 00For
Fidelity1,251,6260 00For
State Street925,01576 00For
Loomis Sayles800,9350 00For
PROFESSIONALLY MANAGED PORTFOLIOS570,0000 00For
Charles Schwab567,3920 00For
Columbia Threadneedle515,8370 00For
Invesco430,6530 00For
Victory Capital334,7980 00For
AMG FUNDS328,1740 00For
MoA Funds Corp273,6300 00For
Brighthouse272,3140 00For
Bridge Builder Trust264,2700 00For
T. Rowe Price234,3110 00For
TIAA226,9320 00For
Tributary Funds, Inc.225,0050 00For
John Hancock189,3910 00For
Lincoln Financial176,2180 00For
THIRD AVENUE TRUST159,7170 00For
Empower152,4740 00For
Jackson National131,1140 00For
Equitable125,8240 00For

Showing the 25 largest of 99 asset managers. All 99 are in the interactive database (link above).

Largest SUPERNUS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 54,723,356 shares outstanding at the time of that meeting.

Fund voting reports: top SUPERNUS PHARMACEUTICALS INC. shareholders by shares voted on “to approve, on a non-binding basis, the compensation paid to our named executive officers;”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 12.75%
2BlackRock 10.35%
3Dimensional 4.11%
4Delaware/Macquarie 3.79%
5Fidelity 2.29%
6State Street 1.69%
7Loomis Sayles 1.46%
8PROFESSIONALLY MANAGED PORTFOLIOS 1.04%
9Charles Schwab 1.04%
10Columbia Threadneedle 0.94%
Institutional-manager reports: top SUPERNUS PHARMACEUTICALS INC. shareholders by shares voted on “to approve, on a non-binding basis, the compensation paid to our named executive officers;”, 2023-2024
#Asset manager % of shares outstanding
1ARMISTICE CAPITAL, LLC 5.35%
2MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST 4.47%
3BlackRock 3.88%
4Polar Capital Holdings Plc 3.55%
5State Street 3.48%
6Stephens Investment Management Group LLC 2.63%
7GEODE CAPITAL MANAGEMENT, LLC 2.30%
8GW&K Investment Management, LLC 2.02%
9Aristotle Capital Boston, LLC 1.79%
10CONGRESS ASSET MANAGEMENT CO /MA 1.61%

Reported SUPERNUS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

SUPERNUS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock, Inc. and its affiliates10,381,318 18.97%Proxy statement (DEF 14A), proxy filed April 29, 2024
BlackRock8,698,410 15.90%Form 13F, quarter ended March 31, 2024
Vanguard Group6,044,750 11.05%Form 13F, quarter ended March 31, 2024
Armistice Capital, LLC4,650,000 8.50%Proxy statement (DEF 14A), proxy filed April 29, 2024
Jack A. Khattar +3,943,917 7.21%Proxy statement (DEF 14A), proxy filed April 29, 2024
Macquarie Group Limited and its affiliates2,737,721 5.00%Proxy statement (DEF 14A), proxy filed April 29, 2024
Dimensional Fund Advisors2,556,921 4.67%Form 13F, quarter ended March 31, 2024
State Street2,038,646 3.73%Form 13F, quarter ended March 31, 2024
Renaissance Technologies1,333,222 2.44%Form 13F, quarter ended March 31, 2024
Geode Capital1,306,950 2.39%Form 13F, quarter ended March 31, 2024

Percentages above are of 54,723,356 shares outstanding, as reported by SUPERNUS PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At SUPERNUS PHARMACEUTICALS INC.'s shareholder meeting held June 14, 2024, in the 2023-2024 proxy season, 304 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,843 separate fund positions. On the most widely held item on that ballot — to approve, on a non-binding basis, the compensation paid to our named executive officers; — FOR was 95% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SUPERNUS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 17, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SUPERNUS PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

SUPERNUS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “SUPERNUS PHARMACEUTICALS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/supernus-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.